75000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - Condensed Consolidated Statements of Changes in Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Description of Business, Organization and Liquidity link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Strategic Agreements link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Equity Incentive Plans link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Equity Incentive Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Description of Business, Organization and Liquidity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Fair Value Measurements - Schedule of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Investments in Fixed Maturity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurement Key Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Fair Value Measurements - Fair Value Measurement Derivative Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Strategic Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Liabilities (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Equity Incentive Plans - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Equity Incentive Plans - Schedule of Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Equity Incentive Plans - Schedule of Stock-based Compensation Expense Recognized (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Equity Incentive Plans - Schedule of Weighted Average Fair Value Of Stock Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Segment Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Segment Information - Schedule of Reconciles Segment Direct Profit or Loss (Details) link:presentationLink link:calculationLink link:definitionLink Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted Average Exercise Price Per Share, Forfeited / Cancelled Agreement Royalty Term Period From First Sale Agreement royalty term period from first sale. Agreement royalty term period from first sale Measurement Input Probability Rate of Achieving F D A Approval of A Product [Member] Measurement input probability rate of achieving FDA approval of a product. Probability rate of achieving FDA approval of a product Balance, end of the period Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs Balance, beginning of period Balance, beginning of period Balance, end of the period Entity Incorporation, State or Country Code Plan Name [Axis] Entity Current Reporting Status Operating expenses Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies us-gaap_CommonStockSharesAuthorized Common stock, shares authorized (in shares) Number of authorized to issue shares of common stock Investment, Policy [Policy Text Block] Investments Document Fiscal Period Focus Entity Shell Company Segment Reporting, Policy [Policy Text Block] Segments Cash and Cash Equivalent Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents Period in which stock options are exercisable Exercisable, contractual life (Year) Weighted Average Remaining Contractual Life (in years), Exercisable us-gaap_CommonStockSharesIssued Common Stock, Shares, Issued (in shares) Common stock, shares, issued (in shares) Statement [Table] Share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Percent of option exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Statement [Line Items] Other Expense [Member] Other [Member] Entity Filer Category us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders' equity Payables and Accruals [Abstract] Purchase of marketable securities Payments to Acquire Marketable Securities Purchase of marketable securities Weighted Average Exercise Price Per Share, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price QTORIN Rapamycin for Microcystic LM [Member] QTORIN rapamycin for microcystic LM. Cash equivalents Cash and cash equivalents Cash and cash equivalents Stock Options to Purchase Common Stock [Member] Percentage of weighted average cost capital. Percentage Of Weighted Average Cost Capital Weighted average cost of capital Derivative, assumption Derivative Liability, Measurement Input Derivative Liability, Measurement Input QTORIN Rapamycin for Microcystic LM - Government Grant Income [Member] QTORIN rapamycin for microcystic LM - Government grant income. Effective Interest Rate Percentage of Potential Future Royalty Payments Effective interest rate percentage of potential future royalty payments. Effective interest rate percentage of potential future royalty payments Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Non-cash lease operating expense Non cash lease operating expense Non cash lease operating expense. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share-based compensation arrangement by share-based payment award, options, grants in period, gross (in shares) Common Shares Underlying Stock Options, Granted Consultants [Member] Consultants. us-gaap_EarningsPerShareBasic Earnings Per Share, Basic, Total Net income (loss) per share, basic Net loss per share of Common Stock - basic (in dollars per share) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Foreign currency translation gain Common Shares Underlying Stock Options, Outstanding balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Common Shares Underlying Stock Options, Outstanding balance Schedule of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Investments in Fixed Maturity Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] us-gaap_LiabilitiesCurrent Total current liabilities Pre-funded Warrants [Member] Prefunded Warrants [Member] Pre-funded warrants. Prefunded warrants to purchase common stock Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to reconcile net loss income to net cash used in operating activities: Convertible Notes Payable, Noncurrent Convetible notes payable Royalty Agreements [Member] Royalty Agreement [Member] Merger agreement closing date Merger Agreement Closing Date Merger agreement closing date. Stockholders’ equity: Stockholders' deficit: Entity Small Business Accumulated deficit Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit), Total Accumulated deficit Accumulated deficit Preferred Stock [Member] Preferred Stock [Member] Potential future royalty payment Potential future royalty payment. Sale of Stock, Price Per Share Sale of stock, price per share Equity Incentive Plans Share-Based Payment Arrangement [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Amendment Flag us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of warrant or right, number of securities called by warrants or rights (in shares) Number of pre-funded warrants outstanding to purchase common stock Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Entity Address, Postal Zip Code us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Net cash used in operating activities Increase (Decrease) in Operating Lease Liability Payments on operating lease liabilities Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description Common Stock [Member] Common Stock [Member] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price Per Share, Granted Debt Securities, Available-for-Sale [Line Items] Grant income Government Assistance, Income, Increase (Decrease) Government Assistance, Income, Increase (Decrease), Total Entity Address, Address Line One Schedule of Weighted Average Fair Value of Stock Options Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Kathleen Goin [Member] Kathleen goin. Kathleen Goin Fair Value Hierarchy and NAV [Axis] Income Tax, Policy [Policy Text Block] Income Taxes Right-of-use assets Operating Lease, Right-of-Use Asset Operating lease right-of-use assets, net Class of Warrant or Right [Axis] Document Type Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Entity Central Index Key Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Net increase (decrease) in cash and cash equivalents Related Party Transactions [Policy Text Block] Related party transactions. Related Party Transactions us-gaap_CommonStockParOrStatedValuePerShare Common stock, par value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, Maximum Debt Securities, Available-for-Sale, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Total Amortized Cost Debt Securities, Available-for-Sale Debt Securities, Available-for-Sale, Total Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Common Shares Underlying Stock Options, Exercised Stock option exercises (in shares) Exercise of common stock options for cash, net of expense (in shares) Fair Value Adjustments on Derivative Liabilities Contingent Value Right Liability Fair value adjustments on derivative liabilities contingent value right liability. Fair value adjustments on derivative liabilities - contingent value right liability Current Fiscal Year End Date Document Quarterly Report Entity Address, State or Province Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Research and Development Expense, Policy [Policy Text Block] Research and Development Expenses Common Stock, Capital Shares Reserved for Future Issuance Shares available for future grants Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Class of Warrant or Right [Domain] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of Stock-based Compensation Expense Recognized Stock Issued During Period, Value, Stock Options Exercised Stock option exercises Exercise of common stock options for cash, net of expense Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses and Other Current Liabilities Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive loss: Other comprehensive loss: Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Fair Value Measurement Inputs and Valuation Techniques [Table] Measurement Input, Expected Term [Member] Expected term to FDA regulatory approval of a product Relating to Series A through E Preferred stock Series A Through E [Member] Series A Through E [Member] Comprehensive (Loss) Income and Accumulated Other Comprehensive (Loss) Income [Policy Text Block] Comprehensive (loss) income and accumulated other comprehensive (loss) income. Comprehensive Loss and Accumulated Other Comprehensive (Loss) Income Accumulated Other Comprehensive Income (Loss) [Member] AOCI Attributable to Parent [Member] Stockholder's Equity [Table] Stockholder's Equity Preferred stock Preferred stock, $0.001; 10,000,000 shares authorized; 15,617 shares issued and outstanding at September 30, 2025 and December 31, 2024 Preferred stock, $0.001; 10,000,000 shares authorized; 0 and 15,617 shares issued and outstanding at December 31, 2025 and 2024 Minimum [Member] Minimum Financial Instrument [Axis] Current assets: Royalty Percentage Royalty percentage. Royalty percentage Fair Value, Inputs, Level 3 [Member] Level 3 [Member] Liabilities, Fair Value Disclosure [Abstract] Liabilities: Segment Reporting [Abstract] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Unrealized (gain) loss on investments Unrealized Gain (Loss) on Investments Unrealized gain on investments Current liabilities: us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Shares outstanding Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts receivable Commitments and Contingencies Commitments and contingencies (Note 8) General and Administrative Expense [Member] General and administrative Payments of Merger Related Costs, Financing Activities Payment of transaction costs in connection with Reverse Merger Interest Income (Expense), Operating Interest Income (Expense), Operating, Total Interest income, net Nonvoting Common Stock [Member] Non-voting Common Stock [Member] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Contingent Value Right Liability [Member] Contingent Value Right Liability Member. Contingent Value Right Liability [Member] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic, Total Weighted-average number of shares outstanding used in computing net income (loss) per share - basic Weighted-average shares used in computing net loss per share of Common Stock - basic (in shares) Document Information [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate intrinsic value of options exercisable Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Subsequent Events [Text Block] Subsequent Events Cash Stock based compensation expense Stock-based compensation us-gaap_StockholdersEquity Balance Balance Total stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share (in dollars per share) Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Interest expense - royalty agreement Interest Income Expense Nonoperating Royalty Agreement Interest income expense nonoperating royalty agreement. Statement of Stockholders' Equity [Abstract] Available-for-sale Securities Maturity Period Available-for-sale securities maturity period. Available-for-sale securities maturity period Use of Estimates, Policy [Policy Text Block] Use of Estimates Accrued severance, bonus, and retention Accrued Severance, Bonus, And Retention Costs, Current Accrued severance, bonus, and retention costs, current. Over-Allotment Option [Member] Underwritten Public Offering [Member] Entity Address, Address Line Two Fair Value Disclosures [Text Block] Fair Value Measurements ConvertiblePreferredStockBeneficialOwnershipLimitationPercent Percentage of beneficial ownership limitation for convertible preferred stock Convertible preferred stock, common stock ownership limit, percent Measurement Input, Discount Rate [Member] Discount rate [Member] Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Plan Name [Domain] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings Fair value adjustments on derivative liabilities Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Entity [Domain] Research And Development Expenses (Income) Research and development expenses (income). Total research and development Business Description and Basis of Presentation [Text Block] Description of Business, Organization and Liquidity Ligand Development Funding Agreement [Member] Ligand Development Funding Agreement. Ligand Development Funding Agreement [Member] Entity Address, City or Town Number of reportable segments Number of Reportable Segments Security Exchange Name Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Measurement Input Type [Domain] Stockholders' Equity Note [Abstract] Government Grants Government grants. Government Grants [Policy Text Block] Statistical Measurement [Domain] Class of warrant or right, exercise price of warrants or rights (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Class of warrant or right, exercise price of warrants or rights (in dollars per share) Assets, Current Total current assets Stock-based compensation expense Share-Based Payment Arrangement, Expense Document Period End Date Fair Value Hierarchy and NAV [Domain] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Common Shares Underlying Stock Options, Exercisable Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Foreign currency translation gain (loss) Accrued Research and Development Expenses Current Accrued research and development expenses current. Research and development expenses Statement of Financial Position [Abstract] Class of Stock [Axis] Number of unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Liabilities Total liabilities Financial Instruments [Domain] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Diluted (in shares) Denominator for diluted net income (loss) per share - adjusted weighted average shares Denominator for diluted net income (loss) per share - adjusted weighted average shares Weighted-average shares used in computing net loss per share of Common Stock - diluted (in shares) Entity File Number Expected volatility, Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Measurement Input Type [Axis] Fair Value Measurement Derivative Liabilities Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Prepaid expenses and other current assets US Treasury Securities [Member] U.S. Treasury [Member] Number of operating segments Number of Operating Segments Sale of Stock [Domain] Segment Reporting Disclosure [Text Block] Segment Information General and administrative General and Administrative Expense, Total Total general and administrative Common Shares Underlying Stock Options, Forfeited / Cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total Common Shares Underlying Stock Options, Forfeited / Cancelled Voting Common Stock [Member] Voting Common Stock. Aggregate potential future milestone payments remaining under arrangement. Aggregate potential future milestone payments remaining under arrangement Aggregate Potential Future Milestone Payments Remaining under Arrangement Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Total Accrued interest receivable on available-for-sale investment debt securities New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued (Not Yet Adopted) Accounting Standards NumberOfVotesPerShare Represents the number of votes per share Number of votes per share Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Options expiration period Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, Minimum us-gaap_CommonStockSharesOutstanding Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Palvella shares of common stock outstanding Common stock, shares outstanding (in shares) Operating Lease, Liability, Current Less: current portion Less: current portion Current portion of operating lease liability Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Document Transition Report Short-term investments Short-Term Investments Short-Term Investments, Total us-gaap_OperatingExpenses Total operating expenses Research and Development Expense Research and Development Expense, Total Research and development Research and development Convertible Preferred Stock [Member] Convertible Preferred Stock [Member] Unrealized Gain (Loss) on Derivatives Fair value adjustments on derivative liabilities - royalty agreement Statement of Cash Flows [Abstract] Stock Issued During Period, Value, New Issues Issuance of common stock Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Stock Option Activity Assets, Fair Value Disclosure [Abstract] Current assets: Stockholders' Equity Equity [Text Block] Stockholders' Equity Strategic Agreements [Text Block] Strategic agreements. Strategic Agreements Net income (loss) attributable to common stockholders Net loss Net loss Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value of options outstanding Outstanding, intrinsic value Outstanding, intrinsic value Payments totalling to fund development Payments Totalling to Fund Development Payments totalling to fund development. Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Liability for Uncertainty in Income Taxes, Current Uncertain tax positions Assets Assets [Abstract] Noncash Interest Income Expense Royalty Agreement Noncash interest income expense royalty agreement. Non-cash interest income (expense) Non-cash interest expense Non-cash interest expense Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Prepaid expenses and other current assets Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration] Research And Development Tax Credit Receivable Research and development tax credit receivable. German research and development tax credit receivable Document Fiscal Year Focus Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES Accounts payable Research and Development Expense [Member] Research and development Research and development Segment Reporting, Factors Used to Identify Entity's Reportable Segments Schedule of Accrued Expenses and Other Current Liabilities [Table Text Block] Schedule of accrued expenses and other current liabilities. Schedule of Accrued Expenses and Other Current Liabilities Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurements Proceeds from Stock Options Exercised Proceeds from exercise of stock options Fair Value Disclosures [Abstract] Commitments and Contingencies Disclosure [Abstract] Payment for Contingent Consideration Liability, Financing Activities Payment of contingent value right liability Derivative Instrument [Axis] Share-Based Payment Arrangement [Abstract] Total assets measured at fair value Assets, Fair Value Disclosure Sale of Stock [Axis] Derivatives, Policy [Policy Text Block] Derivative Instruments Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash used in investing activities QTORIN CMC [Member] QTORIN CMC Title of 12(b) Security Schedule of Segment Reporting Information, by Segment [Table] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted average exercise price per share, Forfeited/ Cancelled Collaborative Arrangement and Arrangement Other than Collaborative [Table] Sale Of Stock Number Of Additional Shares Issued In Transaction Sale of stock, number of additional shares issued in transaction. Sale of stock, number of additional shares issued in transaction Document Information [Table] Legal Entity [Axis] Change in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price Per Share, Outstanding balance Weighted Average Exercise Price Per Share, Outstanding balance Fair Value, Recurring and Nonrecurring [Table] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other liabilities Measurement Frequency [Domain] Statement of Income Location, Balance [Axis] Trading Symbol Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, Maximum Compensation expense Employee-related Liabilities, Current, Total Compensation expense Financing activities: CASH FLOWS FROM FINANCING ACTIVITIES Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (years) Recurring Basis [Member] Fair Value, Recurring [Member] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Equity Components [Axis] 2024 Equity Incentive Plan Two Thousand And Twenty Four Equity Incentive Plan [Member] Two thousand and twenty four equity incentive plan. 2024 Equity Incentive Plan Equity Component [Domain] Options expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease Period in which the entity must notify an increase in beneficial ownership limitation. Convertible preferred stock, beneficial ownership limitation, notice period before increase (Year) Maximum [Member] Maximum Liabilities, Fair Value Disclosure Total liabilities measured at fair value Statistical Measurement [Axis] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted average exercise price per share, Exercised Common stock Common stock, $0.001 par value; 200,000,000 shares authorized; 14,313,659 and 12,380,933 shares issued and outstanding at March 31, 2026 and December 31, 2025 Salaries and Stock-based Compensation [Member] Salaries and stock-based compensation. Amount of current portion of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements Settlement of contingent value right QTORIN Rapamycin For Cutaneous VM [Member] QTORIN Rapamycin For Cutaneous VM. Deferred Costs, Current Deferred Costs, Current, Total Deferred transaction costs Preferred Stock, Shares Authorized Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized (in shares) Entity Registrant Name Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Two thousand and Ninteen Equity Incentive Plan [Member] Two thousand and Ninteen Equity Incentive Plan. 2019 Equity Incentive Plan Royalty agreement liability Royalty Agreement Liability Royalty agreement liability. us-gaap_OtherNonoperatingIncomeExpense Other income Other Nonoperating Income (Expense), Total Other income (expense), net Additional paid-in capital Subsequent Events [Abstract] Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Income tax benefit (expense) Income tax benefit (expense) Measurement Frequency [Axis] Proceeds from Issuance of Common Stock Net proceeds from offering, after deducting underwriting discounts and commissions and other estimated offering expenses Proceeds from issuance of common stock in connection with equity financing Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Schedule of Fair Value Measurement Key Assumptions Entity Common Stock, Shares Outstanding Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk and Other Risks and Uncertainties Change in fair value of derivative liabilities - royalty agreement Increase (Decrease) in Derivative Liabilities Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive (loss) income Accumulated other comprehensive (loss) income us-gaap_Assets Total assets Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life (in years), Exercisable Income Statement [Abstract] Share-Based Payment Arrangement [Policy Text Block] Stock-Based Compensation Sale of Stock, Number of Shares Issued in Transaction Sale of stock, number of shares issued in transaction Issuance of common stock pursuant to ATM offering program, net of $0.7 million in offering costs (in shares) Stock Issued During Period, Shares, New Issues (in shares) Issuance of common stock (in shares) us-gaap_EarningsPerShareDiluted Earnings Per Share, Diluted, Total Net income (loss) per share, diluted Net loss per share of Common Stock - diluted (in dollars per share) Schedule of Reconciles Segment Direct Profit or Loss Schedule of Segment Reporting Information, by Segment [Table Text Block] Increase (Decrease) in Accounts Payable, Trade Accounts payable Account payable ConvertiblePreferredStockCommonStockOwnershipLimitPercent Percentage of common stock ownership limit of convertible preferred stock Convertible preferred stock, common stock ownership limit, percent City Area Code Segment Reporting Information [Line Items] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Derivative Liability, Current Derivative liabilities - contingent value right liability Derivative liabilities - contingent value right liability Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period us-gaap_OperatingIncomeLoss Operating loss Loss from operations Accumulated Deficit [Member] Retained Earnings [Member] us-gaap_ShareBasedCompensation Stock-based compensation Liabilities, Noncurrent Liabilities, Noncurrent, Total Long-term liability Operating Lease, Liability, Noncurrent Long-term portion of lease liability Long-term portion of operating lease liability Fair Value, Inputs, Level 1 [Member] Level 1 [Member] us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by (used in) financing activities Other income Other (expense) income: Derivative Liability, Noncurrent Derivative liabilities - royalty agreement Maximum Payments to Receive upon Achievement of Milestones Maximum payments to receive upon achievement of milestones. Maximum payments to receive upon achievement of milestones Derivative Contract [Domain] Change in Fair Value of Derivative Liabilities - Contingent Value Right Liability Change in fair value of derivative liabilities - contingent value right liability Change in fair value of derivative liabilities - contingent value right liability Debt Securities, Available-for-Sale [Table] Entity Interactive Data Current Stockholder's Equity [Line Items] Stockholder's Equity Statement of Income Location, Balance [Domain] Operating activities: CASH FLOWS FROM OPERATING ACTIVITIES U.S. Treasury U.S. Treasury Fair Value Disclosure U.S. treasury fair value disclosure. Convertible Preferred Stock, Shares Issued upon Conversion Conversion of preferred stock Convertible preferred stock, shares issued upon conversion (in shares) Accretion (Amortization) of Discounts and Premiums, Investments Accretion on marketable securities Agreement Termination Notice Period Agreement termination notice period. Agreement termination notice period Noncash Interest Expense (Income) Royalty Agreement Non-cash interest expense (income) royalty agreement. Non-cash interest expense - royalty agreement Entity Tax Identification Number Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Effect of exchange rate change on cash and cash equivalents Local Phone Number Other Other Liabilities, Current Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized compensation cost Contingent value rights agreement amount paid Contingent Value Rights Agreement amount paid Contingent value rights agreement amount paid. Payments of Financing Costs Payments of Financing Costs, Total Payment of financing cost in connection with equity financing Accounting Policies [Abstract] Class of Stock [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Expected to be recognized over a remaining weighted-average service period Accrued Professional Fees, Current Professional fees Entity Emerging Growth Company